Baales-luna M, Figueroa-vega N, Marn-aragn CI, Perez-luque E, Ibarra-reynoso L, Gallardo-blanco HL, Lpez-aguilar I, Malacara JM (2020) Associations of nicotidamide- N -methyltransferase, FTO, and IRX3 genetic variants with body mass index and resting energy expenditure in Mexican subjects
Research Quality Standards for Copper Peptide Protocols Accurate GHK-Cu administration research depends on compound purity and copper-complex integrity
Cagrilintide vs semaglutide (Wegovy/Ozempic) Mechanism: Cagrilintide: Amylin receptor agonist Semaglutide: GLP-1 receptor agonist Different pathways Weight loss: Cagrilintide alone: 10-12% Semaglutide alone: 10-15% Similar efficacy monotherapy Gastric emptying: Cagrilintide: Very strong delay Semaglutide: Moderate delay Cagrilintide more powerful Side effects: Cagrilintide: More GI effects (stronger gastric slowing) Semaglutide: Moderate GI effects Cagrilintide harder to tolerate for some Availability: Cagrilintide: Investigational (not approved) Semaglutide: FDA approved, widely available Semaglutide easier to obtain currently Combination potential: Synergistic together (CagriSema) 15-25% weight loss combined Best of both mechanisms Verdict: Similar monotherapy efficacy, but combine for maximum results
No jitters, just the little bit of help needed to lose the extra COVID weight
